Advanced search
Publication Cover
HIV Research & Clinical Practice Volume 24, 2023 - Issue 1
Submit an article Journal homepage
899
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study

Hernando Knobel1 Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain;2 Department of Medicine and Life Sciences (MELIS), Univ. Pompeu Fabra, Barcelona, Spain;3 Centro de Investigación Biomédica en Red en Infecciones (CIBERINFECC), Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3186-6416View further author information
ORCID Icon,
Esperanza Cañas-Ruano1 Department of Infectious Diseases, Hospital del Mar, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-4651-7545View further author information
ORCID Icon,
Ana Guelar1 Department of Infectious Diseases, Hospital del Mar, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0001-6697-2652View further author information
ORCID Icon,
Pablo Knobel4 Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, USAORCID Iconhttps://orcid.org/0000-0001-6902-0286View further author information
ORCID Icon,
Judit Villar-García1 Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain;2 Department of Medicine and Life Sciences (MELIS), Univ. Pompeu Fabra, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-6767-3424View further author information
ORCID Icon,
Alicia González-Mena1 Department of Infectious Diseases, Hospital del Mar, Barcelona, SpainView further author information
,
Ceclia Canepa1 Department of Infectious Diseases, Hospital del Mar, Barcelona, SpainORCID Iconhttps://orcid.org/0009-0001-0908-0719View further author information
ORCID Icon,
Itziar Arrieta-Aldea1 Department of Infectious Diseases, Hospital del Mar, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-4655-4151View further author information
ORCID Icon,
Augustin Marcos1 Department of Infectious Diseases, Hospital del Mar, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-5784-2546View further author information
ORCID Icon,
Agustí Abalat-Torrres5 Department of Pharmacy, Hospital del Mar, Barcelona, SpainView further author information
&
Roberto Güerri-Fernández1 Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain;2 Department of Medicine and Life Sciences (MELIS), Univ. Pompeu Fabra, Barcelona, Spain;3 Centro de Investigación Biomédica en Red en Infecciones (CIBERINFECC), Madrid, SpainORCID Iconhttps://orcid.org/0000-0002-9794-9161View further author information
ORCID Icon show all
Article: 2239564 | Received 06 Jun 2023, Accepted 17 Jul 2023, Published online: 26 Jul 2023

References

  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv. Accessed February 01, 2023.
  • Cahn P, Sierra Madero J, Arribas JR, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. AIDS. 2022;36(1):39–48.
  • Osiyemi O,De Wit S,Ajana F, et al. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial. Clin Infect Dis. 2022;75(6):975–986. https://doi.org/10.1093/cid/ciac03635079789
  • Ambrosioni J, Rojas Liévano J, Berrocal L, et al. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre. J Antimicrob Chemother. 2022;77(4):1133–1139.
  • Gallant J, Lazzarin A, Mills A, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390(10107):2063–2072.
  • Baldin G, Ciccullo A, Lombardi F, et al. Short communication: comparing lamivudine + dolutegravir and bictegravir/emtricitabine/tenofovir alafenamide as switch strategies: preliminary results from clinical practice. AIDS Res Hum Retroviruses. 2021;37(6):429–432.
  • Llibre JM, Brites C, Cheng C-Y, et al. Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: results through week 144 from the phase 3, noninferiority TANGO randomized trial. Clin Infect Dis. 2023;76(4):720–729.
  • Ciccullo A, Borghi V, Giacomelli A, et al. Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding. J Acquir Immune Defic Syndr. 2021;88(3):234–237.
  • Sax PE, Rockstroh JK, Luetkemeyer AF, et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin Infect Dis. 2021;73(2):e485–e493.
  • Revollo B, Viñuela L, de la Mora L, et al. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression. J Antimicrob Chemother. 2022;77(6):1738–1740.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.